Peptides Containing Saccharide Radicals, E.g., Bleomycins, Etc. Patents (Class 530/322)
-
Patent number: 8680056Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: May 3, 2007Date of Patent: March 25, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Publication number: 20140079701Abstract: The invention is based, at least in part, on the finding that linker peptides which lack the amino acid sequence GSG reduce or eliminate the addition of posttranslational modifications to the polypeptides which comprise them. More specifically, the novel linker peptides disclosed herein reduce the ability of enzymes to link carbohydrate adducts to polypeptides comprising these linker peptides, e.g., reduce the ability of xylosyltransferase to link xylose to polypeptides. These novel linker peptides, molecules comprising same, and methods of their use are described.Type: ApplicationFiled: December 22, 2011Publication date: March 20, 2014Applicant: BIOGEN IDEC MA INC.Inventors: Brian Robert Miller, Scott Glaser, Justin Caravella, Susan Foley, Xiaoping Hronoeski, Tigran Dikran Alvazian
-
Publication number: 20140079770Abstract: The present invention provides a liposome having excellent lung migration ability that had not existed hitherto, by including GALA or Chol-GALA in the liposome. Furthermore, by using the liposome, a pulmonary delivery carrier having a stronger knockdown effect of siRNA when compared to existing carriers is provided.Type: ApplicationFiled: March 13, 2012Publication date: March 20, 2014Applicants: TAIHO PHARMACEUTICAL CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventors: Kenji Kusumoto, Hideyoshi Harashima, Hidetaka Akita, Hiroto Hatakeyama, Taichi Ishitsuka
-
Publication number: 20140079777Abstract: Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: SAVARA, INC.Inventors: John Lord, Jaakko Taneli Jouhikainen, Herman E. Snyder, Pravin Soni, Mei-Chang KUO
-
Publication number: 20140065175Abstract: The invention relates to the technological sector of the transport and delivery of molecules into cells, either at cytoplasm or at nucleus or inter-cells (cell to cell transport), using peptides binding proteins from the cell microtubule motor complex, preferably dynein-binding peptides, as carrier/delivery peptides; or functionalized structures, as nanoparticles, linked to said carrier/delivery peptides. This delivery can be useful in many technical fields comprising, among some others: diagnosis, therapy and pharmacology.Type: ApplicationFiled: February 17, 2012Publication date: March 6, 2014Inventors: M. Covadonga Alonso Martí, José Ángel Martínez Escribano
-
Publication number: 20140066370Abstract: The disclosure provides Polypeptide Conjugates with multiple improved pharmacological and pharmacokinetic properties and their use in treating various diseases and conditions, such as diabetes and/or obesity.Type: ApplicationFiled: November 23, 2010Publication date: March 6, 2014Applicant: Amylin Pharmaceuticals, LLCInventors: Behrouz Bruce Forood, Soumitra S. Ghosh, James L. Trevaskis, Chengzao Sun, Odile Esther Levy, Lawrence J. D'Souza, Christopher J. Soares
-
Publication number: 20140066592Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.Type: ApplicationFiled: October 11, 2013Publication date: March 6, 2014Applicant: City of HopeInventors: Hua YU, Marcin KORTYLEWSKI, Richard JOVE, Piotr Marek SWIDERSKI, John J. ROSSI
-
Patent number: 8664181Abstract: A prodrug comprising at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule is described.Type: GrantFiled: February 15, 2008Date of Patent: March 4, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Irmgard Merfort
-
TRANSPORT AGENTS FOR CROSSING THE BLOOD-BRAIN AND INTO BRAIN CANCER CELLS AND METHODS OF USE THEREOF
Publication number: 20140056820Abstract: The present invention discloses methods and materials for delivering a cargo compound into a brain cancer cell and/or across the blood-brain barrier. Delivery of the cargo compound is accomplished by the use of protein transport peptides derived from Neisseria outer membrane proteins, such as Laz. The invention also provides synthetic transit peptides comprised of the pentapeptide AAEAP. The invention further discloses methods for treating cancer, and specifically brain cancer, as well as other brain-related conditions. Further, the invention provides methods of imaging and diagnosing cancer, particular brain cancer.Type: ApplicationFiled: September 30, 2013Publication date: February 27, 2014Applicant: The Board of Trustees of the University of IllinoisInventors: Chang Soo Hong, Tohru Yamada, Arsenio M Fialho -
Publication number: 20140056811Abstract: The present invention is related to peptides, which are suitable for use as cell-penetrating peptides (CPPs), variants thereof and/or complexes, fusion molecules and/or conjugates comprising same, use thereof for manufacture of compositions for diagnosing, treating and/or preventing of medical conditions.Type: ApplicationFiled: December 26, 2011Publication date: February 27, 2014Applicant: COMPUGEN LTD.Inventors: Etai Jacob, Amir Toporik, Ronen Shemesh, Ofer Levy
-
Publication number: 20140058062Abstract: [Technical Promblem] To provide a method for manufacturing that enables to obtain a targeted glycopeptide harboring a sialyl sugar chain in high yield without decomposing sialic acid at a non-reducing terminal of sugar chain when the glycopeptide is synthesized by a Boc solid phase synthesis method. [Solution to Problem] The present invention is characterized in that the Boc-sialylglycosylated amino acid derivative used in Boc solid phase synthesis method is one where the carboxyl group of the sialic acid at the sugar chain non-reducing terminal is protected with a phenacyl group.Type: ApplicationFiled: March 5, 2012Publication date: February 27, 2014Applicant: Glytech, Inc.Inventors: Yasuhiro Kajihara, Masumi Murakami, Kazuyuki Ishii
-
Patent number: 8660753Abstract: The present invention relates to a control method of a wheel alignment apparatus using an MDPS, which determines whether or not to cancel center alignment control due to a trouble or error is preferentially determined prior to each control step and then performs control when wheels of a vehicle having an MDPS mounted therein are aligned, such that the trouble or error is preferentially considered in the control priority, thereby increasing driver's convenience and improving safety performance for protecting the driver.Type: GrantFiled: May 2, 2013Date of Patent: February 25, 2014Assignee: Hyundai Mobis Co., Ltd.Inventor: Jeong Ku Kim
-
Publication number: 20140051625Abstract: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicant: MBC Pharma, Inc.Inventors: Alexander Karpeisky, Shawn Patrick Zinnen
-
Publication number: 20140051637Abstract: The purpose of the invention is to provide a novel therapeutic agent for Alzheimer's disease and use thereof. Provided is a therapeutic agent for Alzheimer's disease, which contains a CpG oligodeoxynucleotide structure having a brain migration and improved stability or a salt thereof as an active ingredient.Type: ApplicationFiled: April 25, 2012Publication date: February 20, 2014Applicant: NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITYInventors: Akio Suzumura, Tetsuya Mizuno
-
Publication number: 20140045218Abstract: A surfactant produced by reacting naturally occurring polysaccharides that are not water soluble with a hydrophilic substituent on a carboxylic portion of the polysaccharide. In a second reaction, the surfactant is further substituted on a hydroxylic portion with a hydrophobic or lipophilic substituent, so as to make the reaction product both water soluble and capable of attracting oily material that is hydrophobic to be removed from a substrate by cleaning in water. Methods of making the surfactant and the follow-on reaction product are described.Type: ApplicationFiled: March 15, 2013Publication date: February 13, 2014Applicant: University of MassachusettsInventors: Zarif Farhana Mohd Aris, Ryan M. Bouldin, Ramaswamy Nagarajan, Bridgette Budhlall, Vishal Bavishi
-
Publication number: 20140045763Abstract: The current invention provides new compounds for treating, delaying and/or preventing a human genetic disorder such as myotonic dystrophy type 1 (DM1), spino-cerebellar ataxia 8 and/or Huntington's disease-like 2 caused by expansions of CUG repeats in the transcripts of DM1/DMPK, SCA8 or JPH3 genes.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: PROSENSA TECHNOLOGIES B.V.Inventors: Maria Begoña Aguilera Diez, Peter Christian de Visser, Susan Allegonda Maria Mulders
-
Publication number: 20140044669Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.Type: ApplicationFiled: October 17, 2013Publication date: February 13, 2014Applicant: CERULEAN PHARMA INC.Inventors: Jianjun Cheng, Mark E. Davis, Kay T. Khin
-
Publication number: 20140039039Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: ApplicationFiled: October 15, 2013Publication date: February 6, 2014Applicant: NOVARTIS AGInventors: Gregory HINKLE, Satyanarayana KUCHIMANCHI, Stuart MILSTEIN, Markus WARMUTH, Wenlai ZHOU, Ping ZHU, Tracy S. ZIMMERMANN
-
Publication number: 20140038290Abstract: The present invention discloses an extracellular matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid.Type: ApplicationFiled: August 18, 2011Publication date: February 6, 2014Inventors: V. Prasad Shastri, Aurélien Forget
-
Publication number: 20140038886Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.Type: ApplicationFiled: February 10, 2012Publication date: February 6, 2014Applicant: RUPRECHT-KARIS-UNVERSITAT HEIDELBERGInventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn
-
Publication number: 20140027655Abstract: A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid.Type: ApplicationFiled: November 8, 2012Publication date: January 30, 2014Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Ramot at Tel-Aviv University Ltd.
-
Publication number: 20140024604Abstract: Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.Type: ApplicationFiled: July 17, 2013Publication date: January 23, 2014Applicant: THERAVANCE, INC.Inventor: Michael R. Leadbetter
-
Patent number: 8629114Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.Type: GrantFiled: June 3, 2012Date of Patent: January 14, 2014Assignee: Ophidion Inc.Inventor: Andreas Walz
-
Publication number: 20140011977Abstract: The present invention provides a chimeric molecule including a base-pairing segment that binds specifically to a single-stranded nucleic acid molecule; and a moiety that modulates splicing or translation. The invention also provides a chimeric molecule including a base-pairing segment that binds specifically to a double-stranded nucleic acid molecule; and a peptide that modulates transcription, wherein the peptide comprises up to about one hundred amino acid residues.Type: ApplicationFiled: May 23, 2013Publication date: January 9, 2014Inventors: Adrian R. Krainer, Luca Cartegni
-
Patent number: 8623378Abstract: The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein.Type: GrantFiled: January 31, 2011Date of Patent: January 7, 2014Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Jennifer R. Allen, Govindaswami Ragupathi, Philip O. Livingston, Lawrence Williams
-
Publication number: 20140004175Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.Type: ApplicationFiled: June 18, 2013Publication date: January 2, 2014Applicant: Compugen Ltd.Inventors: Yossef KLIGER, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
-
Publication number: 20130338338Abstract: The invention relates to relatively short peptides (termed ?-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.Type: ApplicationFiled: June 6, 2013Publication date: December 19, 2013Applicants: COGNETIX, INC., THE UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Maren WATKINS, Baldomero M. OLIVERA, David R. HILLYARD, J. Michael McIntosh, Robert M. JONES
-
Publication number: 20130337028Abstract: The present invention relates to synthetic peptides for use in bone tissue repair and regeneration applications. The present invention also relates to various compositions and devices (including implantable orthopedic/dental devices) that contain the synthetic peptides of the present invention, and methods involving the use of the synthetic peptides of the present invention. The present invention also relates to a bone replacement or bone-reconstructive material, which includes a polymer matrix and a synthetic peptide of the present invention.Type: ApplicationFiled: June 22, 2011Publication date: December 19, 2013Applicant: NANOVIS, INC.Inventors: Ganesan Balasundaram, Matthew Hedrick
-
Publication number: 20130338422Abstract: The present invention relates to an anticancer prodrug consisting of peptide of acetyl-SEQ ID NO: 1-linker-anticancer drug. The anticancer prodrug effectively provides an anticancer drug unstable in acid or base, such as doxorubicin, in a form of prodrug. Thus, the anticancer prodrug exists as a non-toxic inactive form when administered into the body, but effectively releases the anticancer drug as an active ingredient in the target area in the presence of caspase activated by radiation or UV treatment after administered into the body. Accordingly, the anticancer drug exhibits selective anticancer effects on cancer cells, thereby maximizing the therapeutic effect and minimizing the side-effects of chemotherapy.Type: ApplicationFiled: March 2, 2011Publication date: December 19, 2013Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Ju-Hee Ryu, Kwang-Meyung Kim, Ick-Chan Kwon, Kui-Won Choi, Sang-Yoon Kim, Beom-Suk Lee, Dae-Yoon Chi, Hee-Seup Kil, Hyun-Ju Sung
-
Patent number: 8609368Abstract: Provided is a process for purifying a vancomycin wet body, comprising: dissolving a wet body obtained from a microorganism-fermented solution containing vancomycin into a water soluble solvent to a concentration of about 1 to 40 g/L and carrying out reverse osmosis filtration; and carrying out lyophilization of the filtered vancomycin. The process for purifying a vancomycin wet body provides high-purity vancomycin, while avoiding degradation of stability during a drying step.Type: GrantFiled: November 26, 2009Date of Patent: December 17, 2013Assignees: Genotech Co., Ltd., Samyang Biopharmaceuticals CorporationInventors: Jin Suk Cho, Jong Won Yoon, Eun Soo Choi, Jeong Min Kim, Ho Joon Choi, Sung Hag Kim, Seong Kyu Kim, Jae Jong Kim
-
Publication number: 20130324478Abstract: The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools.Type: ApplicationFiled: November 19, 2012Publication date: December 5, 2013Inventor: Laurence Faure
-
Publication number: 20130323774Abstract: The present invention provides homogenous, fully-glycosylated, full length erythropoietin and the methods of producing the same.Type: ApplicationFiled: April 30, 2013Publication date: December 5, 2013Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Samuel J. Danishefsky, Ping Wang, Suwei Dong, Malcolm Andrew Stephen Moore, Jae-hung Shieh, John Andrew Brailsford
-
Publication number: 20130323169Abstract: The present invention relates to linker molecules that readily conjugate cellular recognition ligand at one end and drug payload at the other, and are useful in treating or preventing cancer, an autoimmune disease, an inflammatory condition, a central nervous system disorder or an infection.Type: ApplicationFiled: May 31, 2013Publication date: December 5, 2013Inventors: Ze-Qi Xu, Qianli Wang, Augustine Rudolph Joseph, Zhiqiang Fang
-
Publication number: 20130323187Abstract: The present invention describes material and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: ApplicationFiled: November 26, 2012Publication date: December 5, 2013Applicant: PARTNERSHIP & CORP. TECHNOLOGY TRANSFERInventors: Nicolas Fasel, Amal Kuendig
-
Publication number: 20130316463Abstract: A method of purifying a glycan and/or a glycoconjugate comprising the steps of: (a) providing a stationary phase that comprises cotton; (b) applying a glycan and/or glycoconjugate-containing sample to the stationary phase; (c) washing the stationary phase with a first solvent; and (d) eluting the glycan and/or glycoconjugate from the stationary phase with a second solvent. A kit for purifying a glycan and/or glycoconjugate, the kit comprising: a stationary phase comprising cotton; and instructions for purifying a glycan and/or glycoconjugate according to the disclosed method.Type: ApplicationFiled: February 10, 2012Publication date: November 28, 2013Applicants: F. HOFFMAN-LA ROCHE AG, LEIDEN UNIVERSITY MEDICAL CENTERInventors: Manfred Wuhrer, Mahdi Hemayatkar, Maurice Henricus Johannes Selman
-
Patent number: 8591910Abstract: The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule.Type: GrantFiled: July 6, 2012Date of Patent: November 26, 2013Assignee: Altermune Technologies LLCInventor: Kary B. Mullis
-
Publication number: 20130303727Abstract: Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed.Type: ApplicationFiled: July 16, 2013Publication date: November 14, 2013Inventors: Stephen S. Ulrey, Michael B. DeMarco, Li Sun, Mark W. Turbergen, Thomas J. Paulus
-
Publication number: 20130295099Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.Type: ApplicationFiled: February 11, 2011Publication date: November 7, 2013Applicant: The Governors of the University of AlbertaInventors: Christine SZYMANSKI, Harald NOTHAFT
-
Publication number: 20130296252Abstract: Provided are MUC18 targeting peptides which may be used, e.g., to therapeutically target B-1 lymphocytes to reduce the influence of these cells on the metastatic potential of melanoma cells and/or to target cancerous cells, including certain melanoma and leukemia cells. MUC18 targeting peptides may be comprised in fusion constructs, imaging constructs, and/or therapeutic constructs such as fusion constructs which may be used for diagnosing or treating a cancer.Type: ApplicationFiled: April 29, 2013Publication date: November 7, 2013Inventors: Fernanda STAQUICINI, Renata PASQUALINI, Wadih ARAP
-
Patent number: 8575103Abstract: Permeable Switch Region I and II peptides in the range of 9 to 25 amino acid residues in length are provided for specifically inhibiting signaling through G? subunits. In addition, compositions and methods for inhibiting platelet aggregation and ?11b?3 integrin activation using the Switch Region I and II peptides are provided.Type: GrantFiled: March 21, 2012Date of Patent: November 5, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Guy Le Breton, Jin-Sheng Huang, Subhashini Srinivasan, Fadi T. Khasawneh
-
Patent number: 8574871Abstract: The present application relates to genetically modified yeasts for the production of glycoproteins having optimized and homogeneous glycan structures. These yeasts comprise an inactivation of the Och 1 gene, the integration by homologous recombination, into an auxotrophic marker, of an expression cassette comprising a first promoter, and an open reading frame comprising the coding sequence for an ?-1,2-mannosidase I, and the integration of a cassette comprising a second promoter different from said first promoter and the coding sequence for an exogenous glycoprotein. These yeasts make it possible to produce EPO with an optimized and 98% homogeneous glycosylation.Type: GrantFiled: January 25, 2008Date of Patent: November 5, 2013Assignee: GLYCODEInventors: Christophe Javaud, Vincent Carre
-
Publication number: 20130288986Abstract: Described herein is a cyclodextrin containing polymer conjugate.Type: ApplicationFiled: June 20, 2013Publication date: October 31, 2013Inventors: Mark E. Davis, Jungyeon Hwang, Tianyi Ke, Ching-jou Lim, Thomas Schluep
-
Publication number: 20130288955Abstract: A novel pharmaceutical composition comprising a compound of formula (I) is disclosed. The novel compound can include a pharmaceutically acceptable carrier. The invention further comprises methods for making compounds of formula (I) using Dbv29, and to the use of compound of formula (I) to treat bacterial infections.Type: ApplicationFiled: July 10, 2013Publication date: October 31, 2013Inventors: Tsung-Lin Li, Yu-Chen Liu, Yi-Shan Li, Syue-Yi Lyu
-
Patent number: 8569241Abstract: Provided are a composition for improving the brain function, which can be orally taken at a low dose, and a method therefor. The composition for improving the brain function contains, as the active ingredient, X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is nil or represents Ile or Asn-Ile; and Y is nil or represents Val-Met), X-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (wherein X is abscent or represents Thr-Gln-Thr-Pro, Pro-Leu-Thr-Gln-Thr-Pro, Leu-Thr-Gln-Thr-Pro or Pro; and Y is abscent or represents Val-Met), or a salt of the same. The method for improving the brain function comprises administering said peptide or a salt of the same.Type: GrantFiled: June 25, 2012Date of Patent: October 29, 2013Assignee: Calpis Co., Ltd.Inventors: Kazuhito Ohsawa, Naoto Uchida, Kohji Ohki, Hiroaki Goto
-
Publication number: 20130281382Abstract: Novel stable, concentrated, biologically active and ready-to-use lipid-comprising drug delivery complexes and methods for their production are described. The biological activity of the complexes produced are comparable to the formulations prepared according to the prior art admixture method and upon purification, the complexes produced by the method of this invention are 50 to 500 fold more concentrated than the complexes formed by admixture. The method described herein provides for the large scale production of lipid-comprising drug delivery systems useful for gene therapy and other applications.Type: ApplicationFiled: December 12, 2012Publication date: October 24, 2013Inventors: Leaf HUANG, Xiang GAO, Frank L. SORGI
-
Publication number: 20130281658Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.Type: ApplicationFiled: June 25, 2013Publication date: October 24, 2013Inventors: David B Rozema, David L Lewis, Darren Wakefield, Eric Kitas, Philipp Hadwiger, Jon Wolff, Ingo Röhl, Peter Mohr, Torsten Hoffmann, Kerstin Jahn-Hofmann, Hans Martin Mueller, Günther Ott, Andrei V Blokhin, Jonathan D Benson, Jeffrey C Carlson
-
Publication number: 20130281368Abstract: A stretching and exercise device has a first strap member having a pair of end portions, a second strap member having a pair of end portions, and a pair of resistance members connected between respective end portions of the first and second strap members. A third strap member has a pair of end portions attached to respective first and second surface portions of the second strap member. A fourth strap member is attached to a third surface portion of the second strap member different from the first and second surface portions thereof.Type: ApplicationFiled: June 24, 2011Publication date: October 24, 2013Applicant: BIOUSIAN BIOSYSTEMS, INC.Inventors: Edward Bilsky, Robin Polt, Hanoch Senderowitz
-
Patent number: 8563687Abstract: A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabino-galactan proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAGP), is taught in host cells, including plant host cells.Type: GrantFiled: June 22, 2010Date of Patent: October 22, 2013Assignee: Ohio UniversityInventor: Marcia J. Kieliszewski
-
Publication number: 20130273537Abstract: The invention provides compositions and methods that permit a hybrid nucleic acid molecule to enter a cell and when specifically activated within the cell, the molecule anneals to endogenous cellular RNA and permits the isolation of the RNA.Type: ApplicationFiled: March 15, 2013Publication date: October 17, 2013Inventors: James Eberwine, Ditte Lovatt, Julia Richards, Ivan Dmochowski, Brittani Ruble
-
Publication number: 20130267678Abstract: Provided are compositions and methods that permit a hybrid nucleic acid-peptide molecule to enter a cell and when specifically activated within the cell, the molecule anneals to endogenous cellular RNA and permits the isolation of the RNA.Type: ApplicationFiled: June 7, 2011Publication date: October 10, 2013Applicant: The Trustees of the University of PennsylvaniaInventors: James Eberwine, Ditte Lovatt, Julia Richards, Ivan Dmochowski, Brittani Ruble